Men1 disruption in Nkx3.1-deficient mice results in ARlow/CD44+ microinvasive carcinoma development with the dysregulated AR pathway

[1]  Yi Mi Wu,et al.  Genomic correlates of clinical outcome in advanced prostate cancer , 2019, Proceedings of the National Academy of Sciences.

[2]  Deepak Srinivasan,et al.  Androgen receptor expression reduces stemness characteristics of prostate cancer cells (PC3) by repression of CD44 and SOX2 , 2018, Journal of Cellular Biochemistry.

[3]  M. Rubin,et al.  Linking prostate cancer cell AR heterogeneity to distinct castration and enzalutamide responses , 2018, Nature Communications.

[4]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[5]  Henry W. Long,et al.  Enhancer-Mediated Oncogenic Function of the Menin Tumor Suppressor in Breast Cancer. , 2017, Cell reports.

[6]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[7]  V. Arora,et al.  Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancer , 2015, Nature Reviews Cancer.

[8]  David C. Smith,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[9]  Jiaoti Huang,et al.  Systematic dissection of phenotypic, functional, and tumorigenic heterogeneity of human prostate cancer cells , 2015, Oncotarget.

[10]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[11]  S. Dhanasekaran,et al.  Targeting the MLL complex in castration resistant prostate cancer , 2015, Nature Medicine.

[12]  R. Bristow,et al.  Prostate cancer stem cells: deciphering the origins and pathways involved in prostate tumorigenesis and aggression , 2014, Oncotarget.

[13]  A. Jemal,et al.  Cancer statistics, 2015 , 2015, CA: a cancer journal for clinicians.

[14]  G. Valk,et al.  Breast-cancer predisposition in multiple endocrine neoplasia type 1. , 2014, The New England journal of medicine.

[15]  I. Treilleux,et al.  High incidence of mammary intraepithelial neoplasia development in Men1‐disrupted murine mammary glands , 2013, The Journal of pathology.

[16]  M. Lei,et al.  Menin as a hub controlling mixed lineage leukemia , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[17]  R. Cardiff,et al.  Dual targeting of the Akt/mTOR signaling pathway inhibits castration-resistant prostate cancer in a genetically engineered mouse model. , 2012, Cancer research.

[18]  A. Shilatifard.  The COMPASS family of histone H3K4 methylases: mechanisms of regulation in development and disease pathogenesis. , 2012, Annual review of biochemistry.

[19]  Jiaoti Huang,et al.  The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. , 2012, Cell stem cell.

[20]  Benjamin J. Raphael,et al.  The Mutational Landscape of Lethal Castrate Resistant Prostate Cancer , 2016 .

[21]  S. Dimitrov,et al.  Cell cycle regulated expression of NCoR might control cyclic expression of androgen responsive genes in an immortalized prostate cell line , 2011, Molecular and Cellular Endocrinology.

[22]  M. Shen,et al.  A luminal epithelial stem cell that is a cell of origin for prostate cancer , 2009, Nature.

[23]  P. Carroll,et al.  An oncogenic role for the multiple endocrine neoplasia type 1 gene in prostate cancer , 2009, Prostate Cancer and Prostatic Diseases.

[24]  H. Li,et al.  Highly purified CD44+ prostate cancer cells from xenograft human tumors are enriched in tumorigenic and metastatic progenitor cells , 2006, Oncogene.

[25]  W. Herr,et al.  Leukemia Proto-Oncoprotein MLL Forms a SET1-Like Histone Methyltransferase Complex with Menin To Regulate Hox Gene Expression , 2004, Molecular and Cellular Biology.

[26]  Zhao-Qi Wang,et al.  Pancreatic beta-cell-specific ablation of the multiple endocrine neoplasia type 1 (MEN1) gene causes full penetrance of insulinoma development in mice. , 2003, Cancer research.

[27]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.